Breaking Finance News

Derma Sciences Inc (NASDAQ:DSCI) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $4.58, Derma Sciences Inc (NASDAQ:DSCI) traded 0.86% higher on the day. With the last close up 11.61% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Derma Sciences Inc has recorded a 50-day average of $4.68 and a two hundred day average of $4.21. Volume of trade was down over the average, with 39,356 shares of DSCI changing hands under the typical 54,952

Zacks Investment Research has downgraded Derma Sciences Inc (NASDAQ:DSCI) to Hold in a statement released on 10/11/2016.

On Friday November 13, 2015, Oppenheimer released a statement on Derma Sciences Inc (NASDAQ:DSCI) dropped the target price from $17.00 to $8.00 that suggested an upside of 0.98%.

Performance Chart

Derma Sciences Inc (NASDAQ:DSCI)

With a total market value of $0, Derma Sciences Inc has with a one year low of $2.85 and a one year high of $5.99 .

More About Derma Sciences Inc (NASDAQ:DSCI)

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.